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Q-SEA – a tool for quality assessment of ethics analyses
conducted as part of health technology assessments
Abstract
Introduction: Assessment of ethics issues is an important part of health
technology assessments (HTA). However, in terms of existence of
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developed in comparison to other areas of HTA, such as clinical or cost
effectiveness.
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tematically reviewed the literature on methodology in ethics for HTA,
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Introduction
Health Technology Assessment (HTA) focuses on the
“medical, economic, social, and ethical implications of
the development, diffusion, and use of health technol-
ogies”, such as drugs, medical devices, screening tests
andmedical procedures [1], [2], [3]. However, while ethics
is a recognised dimension of HTA, it is frequently regarded
asmethodologically less well-developed than other areas
of HTA, such as clinical or economic effectiveness [4],
[5], [6], [7], [8], [9].
This is not entirely correct, as numerous methodological
advances have occurred in this space over the last dec-
ade, including: development of methods for integrating
ethics issues into health technology assessments, search
strategies for identifying literature on ethics issues, and
advances inmethodology for identifyingwhen an assess-
ment of ethics issues ought to be conducted as part of
an HTA. Nevertheless, one area of ethics for HTA that in-
deed is considerably underdeveloped in comparison to
other areas of HTA is quality assessment of ethics an-
alyses in HTA [10], [11].
A wide spectrum of ‘ethics analyses’ can be conducted
for HTA purposes [12]. The most basic type of ethics
analysis consists of presenting several arguments for or
against a particular health technology, without claims to
comprehensiveness – often found in early commentaries
or as added information in articles on new technologies,
such as uterus transplantation [13], [14]. A more sophis-
ticated analysis presents a systematic review of the
relevant arguments for and against the technology, leav-
ing to the reader to decide whether overall, the arguments
support or oppose the technology [15]. Still more sophis-
ticated analyses would additionally introduce conceptual
clarifications, and relate arguments to more basic norms
and values – reaching a normative conclusion about the
ethical acceptability of the technology, and potentially
also analysing whether this conclusion varies according
to the adopted perspective – e.g. the patient’s, the
healthcare provider’s, the health system’s, etc. [12]. Ex-
amples of these types of ethics analysis can be found in
the literature [16], [17].
However, different quality criteria apply to different types
of analyses – much like different quality criteria apply to
different types of epidemiological studies. Thus, it is im-
portant to be clear about the target of the proposed
quality assessment instrument. Our focus is on proposing
and demonstrating Q-SEA, the first instrument for quality
assessing ethics analyses at the last two levels. This art-
icle therefore first elaborates Q-SEA, and second, applies
it to a sample systematic review, in order to illustrate and
facilitate its use.
Methods
To generate the instrument, we adopted a rigorous, three-
pronged process, which we have reported previously [10].
Briefly, first, we identified a recent systematic review of
guidelines for integrating ethics issues into health tech-
nology assessments [18], and reviewed in full all of the
included guidelines, searching for criteria for assessing
the quality of ethics analyses. Second, we updated its
search strategy, identifying 420 further documents, which
on application of pre-established inclusion and exclusion
criteria, identified 42 documents for full-text review, and
6 documents for inclusion. Although all 6 recognised the
importance of quality in conducting ethics analyses, no
formal instrument for assessing such quality was pro-
posed. Finally, we also convened two 2-day workshops
of experts inmethodology in ethics for HTA, which focused
on the issue of quality assessment in ethics for HTA. The
workshops yielded a preliminary list of elements for
Q-SEA; the list subsequently underwent multiple rounds
of refinements over email discussions – indeed, undergo-
ing further refinements from the list of items initially
proposed [10]. This, finally, resulted in the Q-SEA instru-
ment presented below.
Results
Q-SEA: An instrument for the quality
assessment of ethics analyses
Q-SEA – Quality Standards for Ethics Analyses – instru-
ment is proposed for assessing the quality of ethics
analyses conducted for HTA purposes. The instrument
consists of elements categorised into two domains: the
process domain and the output domain (Table 1).
The Process Domain
The ‘process’ domain focuses on assessing the quality
of the elements that constitute the process of arriving at
the ethics analysis. The elements in this domain include:
research question, literature search, inclusion and exclu-
sion criteria, perspective, and ethics framework.
i) Research Question
Although the issue of defining a research question in
systematic reviews of ethics issues has been a matter of
some controversy [19], approaches similar to systematic
reviews of clinical evidence have more recently become
generally accepted. For example, McCullough et al. [17]
recommended that a normative systematic review of
clinical ethics literature should address a clinical question
in the PICO format – for example, “In [P] patients with
mental disorders, [I] is use of concealed medications in
food/drink, [C] rather than prescribingmedications in the
usual way or forcibly administering them, [O] ethically
justifiable?” Similarly, in a systematic review of descriptive
ethics, one could ask: “What are the ethics issues relevant
for the assessment, deliberation, decisionmaking, imple-
mentation, and use of non-invasive prenatal testing in
antenatal care?” Both normative and descriptive ethics
analyses lend themselves to clearly stated research
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Table 1: Quality Standards for Ethics Analyses (Q-SEA) in HTA
questions; we therefore remain agnostic on whether the
research question needs to be in the PICO format. How-
ever, it is worth noting that formulation of research
questions in PICO format enables ready translation into
search and information retrieval strategies commonly
used in HTA.
ii) Literature search
The systematic review of ethics issues in HTA –much like
systematic reviews of clinical evidence – require a com-
prehensive search of sources. The comprehensiveness
of a search depends both on how the search strategy is
designed and on the selection of sources of information
[20]. A comprehensive search of ethics issues around a
health technology makes use of a variety of sources, in-
cluding biomedical databases (Medline, EMBASE etc.),
nursing databases (e.g. CINAHL), systematic reviews
databases (e.g. the Cochrane library, CRD-HTA, EuroScan
database), Social Sciences and Psychology databases
(e.g. PsycInfo), and databases with philosophical and
ethical content (e.g. PhilPapers, BELIT, SIBIL, ETHICS-
WEB). Both international and national sources should be
searched, due to the context sensitivity of ethical aspects.
In addition to the electronic databases, it is recommended
to hand search non-indexed journals (e.g. Clinical Ethics)
and anthologies. Searching the reference lists of already
included publications or using a ‘related articles’ feature
(snowballing or hand-searching) can also increase the
comprehensiveness of the search. As in all reviews, the
time period and language restrictions (if any) of the
searches should be clearly stated and justified if potential
for bias exists.
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iii) Inclusion and exclusion criteria
The requirements for inclusion and exclusion criteria in
systematic reviews of ethics issues are similar to system-
atic reviews of other types of evidence. Predefined criteria
should be clearly described and aligned with the research
question. The inclusion and exclusion criteria may be less
strict regarding type of publication than systematic re-
views of clinical effectiveness, as ethical arguments may
very well be found in commentaries or editorials, for ex-
ample. Themost important criterion is that the publication
provides relevant arguments and assessment that can
illuminate moral aspects of the technology [21]. Hence,
a relevant exclusion criterion is publications where ethics
issues are considered only briefly and tangentially [22].
Lack of thoroughness of ethical arguments may also be
an exclusion criteria [23]. The setting of the intervention
can also be a relevant criterion for an ethics analysis –
for example including only publication focusing on hos-
pital-based health professionals in developed countries
[24].
iv) Perspective
Generally, an ethics analysis should be conducted from
an impartial perspective, analysing how the health tech-
nology affects the relevant values and norms for different
stakeholders. However, there are cases where it is appro-
priate for an ethics analysis to adopt a specific perspec-
tive – for example, a healthcare system perspective, pa-
tient perspective, societal perspective, etc. For example,
if a health technology under assessment has the potential
to intrude on the privacy of patients, an analysis looking
at privacy issues from the perspective of patients might
be an acceptable. However, conducting an ethics analysis
from a specific stakeholder perspective does not imply
simply asking about stakeholder views; the outcome of
the ethics analysis might be at odds with stakeholder
views. In that sense, an ethics analysis from a specific
perspective is still impartial. As in the case of economic
or qualitative analyses, where an ethics analysis is con-
ducted from a specific stakeholder perspective, this
should be made clear to the reader.
v) Ethics framework
A wide range of frameworks (also sometimes referred to
as approaches, methods, positions) may be applied in
ethics analyses conducted for HTA. These include: the
Socratic approach, principlism, casuistry, coherence
analysis, participatory HTA approach (iHTA), and others
[25]. What is an appropriate framework to use will vary
by context and the technology under assessment, but
tools for choosing an ethics framework for analyses of
ethics issues for some types of health technologies (e.g.
complex health interventions) already exist [26] and can
be utilised. Other factors relevant to the choice of
framework may include: local preferences, expertise of
those conducting the analysis, time and financial con-
straints, and so on. Nevertheless, whatever framework
is selected, a well conducted ethics analysis ought to
clearly identify the applied framework(s). Clarity about
the choice of framework is important as a certain argu-
ment about a health technology may be understood dif-
ferently if it appears in a utilitarian context compared to
in a deontological context. Explicit identification of the
adopted framework may therefore also help to avoid “in-
terpretation bias”.
The Output Domain
The ‘output’ domain focuses on assessing the quality of
the elements that constitute the output – that is, the
ethics analysis that is the result of the process. The
elements included in the output domain are: complete-
ness, bias, implications, conceptual definitions, and
conflicting values.
i) Completeness
Systematic reviews of ethics issues pose a challenge with
respect to completeness – how to knowwhen all relevant
arguments and issues have been identified. To ensure
completeness of ethics analyses, some authors have
used qualitative research approaches [27], including
thematic analysis,meta-ethnography and content analysis
[28], [29]. Ring et al. report that meta-ethnography, meta-
study, meta-summary, and thematic synthesis were the
most used methods and could be a good starting point
when performing a review of reasons [30]. Thus, a wide
range of methods can be appropriate here, and the par-
ticular methodology adopted will vary by factors such as
the specific question to be addressed, resources, and
expertise of the systematic reviewers. However, it is also
crucial for an adequately performed ethics analysis to
reflect on whether additional – unidentified in the litera-
ture search – relevant ethics issues are raised by the
technology. Identification of gaps in the state of know-
ledge is especially crucial for new and emerging techno-
logies, but also arises for well-established technologies.
If it is unlikely that gaps in the literature around ethics
issues pertaining to specific technology exist, this should
be explicitly indicated, with reasons for this determination.
ii) Bias
Like other types of analyses, ethics analyses may be
subject to bias. Therefore, biases should be explicitly
identified and discussed in an ethics analysis. A series
of potential biases can arise whilst conducting an ethics
analysis for HTA purposes. “Interpretation bias” has
already been mentioned. Bias in the selection of end-
point (“end-point-selection bias”), “perspective bias”,
“search bias”, and bias in the presentation of arguments,
are but a few examples of potential biases in ethics
analysis. Which biases are relevant for an assessment
of ethics issues around a specific health technology in a
given health care and HTA context may vary greatly.
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However, crucial here is that the existence of biases (or
potential biases) is acknowledged, the types of biases
identified, and discussed in an ethics analysis.
iii) Implications
Implications of the ethics analysis need to be clearly and
explicitly presented, as well as differentiated by stakehold-
er group (e.g. patients, healthcare professionals, industry,
etc.). There are differences here with respect to descrip-
tive systematic reviews and normative ones. Although
descriptive systematic reviews aim to identify the issues
that are relevant for decision-making, and do not aim to
make recommendations, they are still able to identify the
implications of the various ethics issues identified, without
making prescriptive recommendations. Conversely, for
normative ethics analyses, it is crucial that the arguments
for specific recommendations are clearly identified and
justified. Similar considerations apply to differentiating
implications by stakeholder groups. Analyses that only
address the ethical implications for one stakeholder group
are of poorer quality than analyses that address implica-
tions for multiple stakeholders.
iv) Conceptual clarification
Ethical concepts are generally “thick concepts” – they
have both a descriptive content and a strong evaluative
component. Thus, their ambiguity and complexity requires
clarification. To some extent, the ethics framework chosen
to conduct the analysis may provide clarifications of eth-
ical concepts, such as beneficence, dignity, etc. However,
the degree (if any) of conceptual clarification provided by
a frameworkmight not be sufficient for use in the specific
analysis of ethics issues, and even where the conceptual
clarifications are provided, it is worth noting that the same
concepts may be differently understood by different eth-
ical frameworks. Moreover, an important part of concep-
tual clarification is to assess whether concepts used have
been applied consistently through the ethics analysis.
Methodology for this type of conceptual clarification exists
– e.g. Brülde’s method of conditions of adequacy for
conceptual clarification. Brulde’s list includes the following
conditions: the ordinary language condition – relating it
to ordinary language use; the value condition – whether
the value-ladenness of the concept is explained; the co-
herence condition – whether the concept is applied con-
sistently; the precision condition – whether the concept
is precise enough; the reliability condition – whether the
concept is used in a transparent way; and the simplicity
condition – whether the concept is simple enough [31].
v) Conflicting values
Values and norms involved in ethical arguments regarding
a specific health technology can be implicit or explicit.
For example, in the assessment of a new type of assisted
reproductive therapy such as mitochondrial donation,
conflicts may arise between the values of reproductive
choice and caution in the face of uncertainty. These value
conflicts may be made explicit or left implicit in an ethics
analysis. However, where they are left implicit, this may
lead to an unwarranted interpretation of the results of
the ethics analysis, biases, and/or in misleading conclu-
sions. High quality ethics analysis therefore ought to ex-
plicitly identify the conflicts of values; whether it is appro-
priate to both identify and balance these conflicts, will
depend on whether the systematic review of ethics issues
is descriptive or normative.
Overall quality assessment
In line with the approach in the Cochrane Handbook, we
recommend avoiding the scale-based approach – that
is, one in which the elements of the quality assessment
tool are scored individually, and combined in an overall
score [32]. Instead, we recommend that both the process
domain and the output domain – together with their
constitutive elements – be critically evaluated, and results
presented narratively.
Application of the Q-SEA instrument
In order to facilitate the use of the Q-SEA instrument, we
present here its application to a systematic review of
ethics issues in autologous stem cell transplantation
(ASTC). This systematic review of ethics issues was con-
ducted as a result of identification of ethics issues sur-
rounding ASTC during a systematic review of the effect-
iveness of ASTC by the German Institute for Quality and
Efficiency in Health Care (IQWiG) [23].
The Process Domain
i) Research Question
An ethics analysis should have a clearly stated research
question. Droste et al. clearly state that their focus is on
“ethical issues related to ASTC [autologous stem cell
transplantation] in locally advanced andmetastatic breast
cancer patients” [23]. Although the research question is
not formulated in the PICO format, three of the compon-
ents of the PICO format are readily identifiable – the
population are the patients with locally advanced and
metastatic breast cancer; the intervention is ASTC; and
the outcomes are ‘ethical issues’.
ii) Literature search
The literature search is very comprehensive, aiming for
high sensitivity of the searches. Searches included both
domestic (German) and international sources. Twenty-
seven databaseswere searched, in the following subjects:
biomedicine, nursing, psychology, social sciences, health
economics, ethics,monographs, and publisher databases.
Additionally, snowballing and citation tracking was carried
out (without further description how, but with reference
to a methods publication). No language restrictions were
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used, and the search period is clearly stated: to January
2008. It bears noting, however, that search terms are
not provided or discussed.
iii) Inclusion and exclusion criteria
The inclusion and exclusion criteria are clearly stated,
and include a number of specific criteria related to the
aim of the study – to review the ethics issues associated
with ASCT. First and second screen inclusion criteria in-
clude, for example, specification regarding the technology
(stem cells), sources (e.g. GermanNational Ethics Council,
or others), types of publications (e.g. health economics
publications that balance harms and benefits). First and
second screen exclusion criteria are likewise provided,
and pertain to (among others): publication focus (absence
of discussion of ethics issues around ASTC), publication
types (e.g. daily newspaper articles), population (e.g.
children), and setting (e.g. publications exclusively fo-
cused on non-European settings).
iv) Perspective
The review of ethics issues indicates (in the background
section) that it is linked to the systematic review of effect-
iveness of ASTC conducted by IQWiG. Because the ana-
lysis utilises the Socratic framework, which includes
questions pertaining specifically to various groups of
stakeholders (e.g. individual patients, society, physicians,
etc.), some information about the perspective can be in-
ferred. The analysis does not appear to take a broad
perspective of health service providers, payers, and other
members of society. Nor does it appear to take any other
specific perspective. The perspective from which the
analysis as whole is conducted, is unclear.
v) Ethics framework
The analysis explicitly states that it adopts a modified
version of the Socratic approach, consisting of Hofmann’s
33 questions [33]. This choice is justified by the aim of
increased transparency and reproducibility, as well as a
desire to address each of the 33 questions inmore detail.
The review, moreover, incorporates a quantitative elem-
ent, listing how many identified references address each
of the 33 questions. Both the choice of the approach and
its modifications are explicitly justified.
The Output Domain
i) Completeness
The review adopts a quantitative approach – identifying
howmany publications address each of the 33 questions.
This allows for an identification of both the saturation
points and the gaps in the literature. Droste et al. found
no literature addressing two of the 33 questions – ques-
tion 8, focusing on whether the technology changes our
conception of persons, and question 30, what are the
interests of those participating in the technology assess-
ment. Although it is understandable why no literature was
found on question 30, the authors of the review do
provide an answer about their motivations – these are:
a desire to identify harms and benefits,make recommend-
ation for financing this treatment, and methodological
development. For question 8, authors acknowledge that
this issue may not have been discussed in the literature,
i.e. remains a gap.
ii) Bias
The review presents ethics issues in a descriptivemanner
and the authors do not evaluate, rate, or discuss the is-
sues. However, the study does address several potential
biases in the results (that is, the ethics issues identified
in the literature) resulting from the applied approach. For
example, it identifies some limitations inherent in the
adopted approach, such as the potential for the loss of
“first-order experiences of patients or patient groups by
analysing the (scientific) published literature”. At the same
time, they acknowledge that “[t]his is not the case in our
example. Our retrieval results included some first-hand
reports.” It also notes the bias in favour of the survivors
in health-related quality of life data. Moreover, it suggests
improvements for future use.
iii) Implications
In adopting the Socratic approach, the study considers
a wide range of ethics issues, and their applicability to
particular stakeholder groups – individual patients (e.g.
challenge to patient autonomy), society (e.g. contesting
of social or cultural convictions), care providers (e.g. im-
pact of the technology on the relationship between
physicians and patients), third parties (e.g. industry and
insurers), etc. However, the policy implications of the
analysis as a whole are not identified either generally, or
as they apply to the different stakeholder groups.
iv) Conceptual clarification
The systematic review makes no explicit assessment of
conceptual issues, and the authors only make some im-
plicit conceptual clarifications in passing. For example,
the authors acknowledge the culturally dependence of
the understanding of “human dignity”. However, a wide
range of ambiguous and vague value-laden concepts –
such as autonomy, equality and dignity – are used in the
review without clarification.
v) Conflicting values
Because the systematic review utilises the Socratic
framework, some of the conflicts of values between
various stakeholders are implicitly apparent from the
discussions of the individual 33 questions. However, the
review does not explicitly reflect on the values implicit in
the arguments. Any decision to fund – or not fund – a
health technology, is inherently laden with conflicts of
values between the stakeholders – patients, healthcare
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providers, decisions-makers, funders, insurers, industry,
and so on. Because the review has as its aim assisting
decision-makers in their decision process, this is a
shortcoming.
Overall quality assessment
Overall, the elements comprising the Process Domain
were completed very well in this review. The research
question was clear, and the literature search very com-
prehensive, although it would have been helpful to have
been provided with a list of search terms used, as is
common in systematic reviews of clinical effectiveness.
The inclusion and exclusion criteria were also very clear.
Because impartiality is crucial in ethics analyses, and the
perspective from which a technology is assessed will im-
pact both what is included and excluded, and the shape
of resultant analysis, the importance of identifying the
perspective is considerable. The perspective adopted in
the present review is only implicitly suggested, and would
benefit from clarification. The ethics framework is clearly
identified, and its use to assess completeness is innova-
tive.
The elements of the Output Domain displayed more
variability in the degree of completion. Bias issues are
considered. On the other hand, policy implications are
not clearly drawn out, conceptual clarifications are not
offered, and value conflicts are also not clarified. The
importance of drawing out policy implications, and value
conflicts between the various stakeholders, in ethics
analyses conducted for HTA purposes is considerable, as
HTA personnel and decision-makers who read such an-
alysis may not be ethicists themselves. The need for
conceptual clarification also cannot be underestimated
in ethics, which traffics in thick, value-laden concepts.
Discussion
To generate the Q-SEA instrument, we adopted a rigorous,
three-pronged process, consisting of: a review of guideline
documents, an update of a search strategy, and solicita-
tion of the views of experts in methodology in ethics for
HTA. As a result, a preliminary version of the Q-SEA instru-
ment has previously been published [10]. However, in
applying this instrument to a specific systematic review
of ethics issues in HTA, modifications were necessary. In
particular, we modified the two domains’ labels, in order
to better reflect their foci – internal quality assessment
and external quality assessment became process domain
and output domain, respectively. Moreover, although we
retainedmany of the elements comprising these domains
(e.g. perspective, implications), we modified others (e.g.
assumptions, premises, conclusions) as in practice, we
found them to be more applicable to evaluating the
quality of individual ethical arguments than to evaluating
systematic reviews of ethics issues as a whole.
Assessment of the quality of systematic reviews in HTA
is essential, and ethics analyses conducted for HTA pur-
poses are not exempt from this requirement. We endeav-
oured to propose an instrument that is usable by both
ethicists and non-ethicists alike. However, as the instru-
ment was generated predominantly by individuals with
expertise in both ethics and HTA, some elements of the
instrument (such as completeness and conceptual
definitions) may be more challenging for non-ethicists to
assess. The Q-SEA instrument may therefore require fur-
ther refinements, based on the feedback from its users.
Conclusion
We propose here Q-SEA, a quality assessment instrument
for ethics analyses conducted for HTA purposes, and
outline its initial application to an ethics analysis previ-
ously conducted for HTA purposes. We believe that the
resulting Q-SEA instrument will fill in the thus far neg-
lected methodological gap in ethics for HTA, and that its
preliminary application, illustrated above, will assist in its
uptake. Further refinements to the instrument are both
expected and planned, in light of the experiences of its
users in conducting quality assessments of ethics an-
alyses pertaining to various health technologies, conduct-
ed for different types of health systems, prepared by HTA
agencies with different remits, and so on. The authors
therefore welcome the feedback from the instrument’s
users.
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